$80

Peptides
Eloralintide
Eloralintide (LY3841136), a selective amylin receptor agonist. Supplied as a lyophilised powder in 10mg vials.
Supplied as lyophilised powder in a 10mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.
Product information
About Eloralintide
LY3841136
Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.
Eloralintide (LY3841136) is a long-acting, selective amylin receptor agonist developed by Eli Lilly. Amylin is a peptide hormone co-secreted with insulin from pancreatic beta cells.
It has been studied as a once-weekly compound in metabolic research. The Phase 2 trial, which enrolled 263 adults across research centres in the United States, was presented at ObesityWeek 2025 and published in The Lancet; Phase 3 studies were announced afterwards. A separate Phase 2 study examines it alongside tirzepatide.
Eloralintide is an investigational compound and not an approved medicine. It is supplied here as a reference material for in-vitro research into amylin receptor pharmacology.
- Type
- Selective, long-acting amylin receptor agonist
- Research Areas
- Amylin receptor signalling, satiety pathways, weight research
- Code Name
- LY3841136
- Developer
- Eli Lilly
- Primary Receptor
- Amylin receptors (AMY1–3)
- Development Stage
- Phase 3 (investigational)
- Regulatory Status
- Not approved
- 01Amylin Receptor SelectivityEloralintide is designed to act selectively at amylin receptors, which are formed by the calcitonin receptor together with receptor activity-modifying proteins (RAMPs). Research compares this selectivity with dual amylin and calcitonin receptor agonists.
- 02Satiety SignallingAmylin receptor agonists are studied for their action on brainstem and hypothalamic circuits involved in satiety and food intake, a pathway distinct from the GLP-1 receptor.
- 03Clinical InvestigationA 48-week randomised, placebo-controlled Phase 2 trial in adults with obesity or overweight was published in The Lancet in 2025. Eloralintide remains investigational and is not approved by any regulator.
References
- 1Billings LK et al. Eloralintide, a selective amylin receptor agonist, in adults with obesity or overweight: a randomised, placebo-controlled phase 2 trial. Lancet. 2025.
- 2ClinicalTrials.gov: NCT06230523.
- 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=eloralintide
Also in this range.
Compounds the supplier files alongside this one.


